Retinal gene therapy Market Outlook 2026–2038: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines retinal gene therapy, meaning gene therapies, optogenetic therapies and encapsulated cell therapies for inherited retinal disease, retinitis pigmentosa, Stargardt disease, macular degeneration and diabetic eye disease. It tests how fast late stage programmes turn into approvals and which participants capture value among developers, large pharmaceutical partners, manufacturers and treatment centres.

Filings are the first change. The US Food and Drug Administration accepted the biologics licence application for MOGENRY (sonpiretigene isteparvovec, formerly MCO-010) from Nanoscope Therapeutics in September 2026 for adults with retinitis pigmentosa and severe vision loss. In the randomised RESTORE trial of 27 patients, the high dose group improved best-corrected visual acuity by 0.337 logMAR against sham at week 52, and long term follow-up reported gains of about three ETDRS lines held to week 152 with no treatment-related serious adverse events. The conclusion is that a therapy designed to work regardless of the causative gene has reached regulatory review, which widens the treatable population beyond single-gene disease.

Other programmes are near the same stage. Ocugen completed phase 3 enrolment of OCU400 for retinitis pigmentosa in March 2026 and has begun rolling submissions, and in July 2026 signed a binding term sheet with Roots Pharmaceutical for the Middle East and North Africa. 4D Molecular Therapeutics completed enrolment in both phase 3 wet macular degeneration trials in 2026, with results expected in 2027. The conclusion is that several filings and readouts fall within the next two years, and the first approvals in common retinal disease would change the size of the market.

The record also shows risk. MeiraGTx reacquired full rights to bota-vec from Johnson & Johnson in April 2026 after the phase 3 LUMEOS study missed its primary endpoint, while still planning filings in 2026. The conclusion is that a trial result alone does not decide approval or partner support, and developers with several programmes are better placed than those with one.

The brief treats retinal gene therapy as an emerging signal with a twelve year horizon to 2038. It identifies which diseases, regions and developers scale first and what each means for developers, large pharmaceutical partners, manufacturers and treatment centres. It is a focused 100-page decision brief that presents an indicative trajectory rather than a segmented market model.

Retinal gene therapy delivers a working gene, or a light-sensitive protein in optogenetic therapy, to cells in the retina using a harmless virus, either by subretinal surgery or by injection into the vitreous.

Gene replacement targets a single faulty gene. Optogenetic therapy gives other retinal cells light sensitivity regardless of the faulty gene, which suits advanced disease.

Performance is measured by best-corrected visual acuity, functional vision tests and durability of response, with ocular inflammation and raised eye pressure the main safety findings.

Uses are inherited retinal disease, retinitis pigmentosa, Stargardt disease, geographic atrophy, wet macular degeneration and diabetic eye disease.

The limits are small populations in inherited disease, surgical risk, limited long term data and treatment cost. The period turns on approvals in retinitis pigmentosa and common retinal disease.

The retinal gene therapy market, covering gene therapies, optogenetic therapies and encapsulated cell therapies for inherited retinal disease, retinitis pigmentosa, Stargardt disease, macular degeneration and diabetic eye disease, and excluding anti-VEGF injections, retinal implants and devices, is valued at USD 0.2–0.4 billion in 2026 and is projected to reach USD 3.87–7.74 billion by 2038, at a CAGR of 28%.

The 2026 base rests on sales of approved gene and cell therapies for rare retinal disease. Growth then follows approvals in retinitis pigmentosa, the first approvals in wet macular degeneration and diabetic eye disease, and expansion to Europe and Asia.

The forecast is sensitive to the outcome of regulatory reviews, the durability of response and pricing. Regionally, North America leads on approvals and sales, Europe and Japan follow through trial sites and agencies, and the Middle East and North Africa open through licensing.

The base case assumes the first optogenetic and retinitis pigmentosa filings are approved by 2028 and wet macular degeneration therapies by 2030. An accelerated case assumes fast reviews and positive phase 3 readouts, bringing the inflection to 2030 and lifting the 2038 value to the top of the range. A delayed case assumes missed endpoints and slow approvals, holding growth at the bottom of the range.

Growth drivers

• Late stage trial results.
• Mutation-agnostic approaches.
• Genetic testing of retinal disease.
• Regulatory incentives for rare disease.

Enablers

• Vector manufacturing capacity.
• Retina surgery centres.
• Patient registries and advocacy groups.
• Academic and hospital research.

Restraints and barriers

• Small patient populations.
• Missed trial endpoints.
• Pricing and access arrangements.
• Limited long term data.

The direction of retinal gene therapy is set by approved precedent, optogenetic approaches that work for any causative gene, intravitreal delivery for common disease, priority regulatory pathways, and treatment cost and access.

The key participants in retinal gene therapy include Novartis AG, Roche Holding AG, Nanoscope Therapeutics Inc., Ocugen, Inc., 4D Molecular Therapeutics, Inc., MeiraGTx Holdings plc, Johnson & Johnson, Beacon Therapeutics Holdings Limited, Adverum Biotechnologies, Inc., REGENXBIO Inc., AbbVie Inc., Atsena Therapeutics, Inc., Neurotech Pharmaceuticals, Inc., GenSight Biologics S.A., Sparing Vision S.A.S., Opus Genetics, Inc., SpliceBio S.L., VeonGen Therapeutics, Inc., Astellas Pharma Inc., Lonza Group AG, Roots Pharmaceutical, GenEditBio, Syncona Limited, Stanford University, University College London, Moorfields Eye Hospital NHS Foundation Trust, Massachusetts Eye and Ear, Institut de la Vision, University of Pennsylvania, Foundation Fighting Blindness, American Academy of Ophthalmology, Association for Research in Vision and Ophthalmology, Alliance for Regenerative Medicine, U.S. Food and Drug Administration, European Medicines Agency, Medicines and Healthcare products Regulatory Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, National Eye Institute and Centers for Medicare & Medicaid Services.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as filings turn into approvals.

Novartis and Roche lead on approved therapy, Nanoscope Therapeutics and Ocugen lead on retinitis pigmentosa filings, and 4D Molecular Therapeutics and REGENXBIO lead in wet macular degeneration. Competitive intensity is moderate in rare disease and rising in common retinal disease.

Where value migrates.

In 2026 value sits with developers of approved therapies and those with filings under review, because patients are few and the first approvals set prices and treatment practice. By 2032 it moves toward developers with several indications, because a single rare disease cannot support a company. By 2038 it settles in platforms that link genetic testing, therapy and follow-up across rare and common retinal disease. Margins hold for developers with approved products in larger indications and narrow for those with one programme in a small population.

The signals converge on filings and late stage readouts. An application under review, completed phase 3 enrolment and durable data over about three years support growth, while the missed endpoint of one programme, small rare disease populations and treatment cost limit the pace.

Structural limits show where progress could slow: small patient populations, missed endpoints, surgical risk, pricing and access, and limited long term data. The brief therefore tracks four indicators: regulatory decisions, trial readouts, patients treated and treatment centres.

Rare inherited disease and retinitis pigmentosa first, then macular degeneration, then diabetic eye disease are the expected order of adoption.